asia 2020 tokyo - biogo.bio.org/rs/490-ehz-999/images/bio asia japan 2020... · 2020. 6. 14. ·...

Accelerate your Pathwayto Partnerships in Asia

MARCH 10-11, 2020 • TOKYO, JAPAN

AsiaInternational Conference

Tokyo2020

#BIOASIA20 • bio.org/asia

General Overview •

Advisory Committee •

Education and Conference Programming •

Partnering •

Sponsorship Opportunities •

2019 Sponsors •

http://bio.org/Asia

Event Attributes and Opportunities

• Gain insights into the changes, challenges, and opportunities key opinion and policy leaders foresee for the Japanese biotech market.

• Facilitate connections with strategic partners looking to invest, partner, or license in or license out, early to late-stage programs in your therapeutic area of focus.

• Opportunity for organizations to deliver company presentations, providing increased visibility in front of a global audience of biotech and pharmaceutical companies, all interested in cross-border business development alliances and research collaborations.

• BIO One-on-One Partnering enables attendees to search company and investor profiles, drug assets, products, and services in the biopharma industry; evaluate potential

collaborations and funding opportunities with participating companies; communicate directly with conference attendees; and pre-schedule private, 30 minute One-on-One meetings to be conducted onsite.

• Panel discussions will increase your understanding of, and interaction with, the Japanese biotech market, the political landscape in Japan, and its impact on this important industry sector.

• Network with government leaders, peers, investors, and potential partners attending the conference and our exclusive welcome reception.

• Exclusive sponsorship opportunities to showcase thought leadership, elevate brand identity and maximize partnering benefits with an elite audience.

The BIO Asia International Conference is an exclusive partnering forum that brings together the global biotechnology and pharmaceutical industry to explore licensing and investor engagement in the current Asia-Pacific business and policy environments.

WHO SHOULD ATTEND:• Drug development and discovery companies

• Biopharmaceutical companies

• Medical technology companies

• Universities and institutes

• Intellectual property and legal organizations

• Investors and financial services providers

• Bio-clusters and incubators

• Government and public support agencies

CO-HOSTED BY: ®

ATTENDANCE BY REGION

Asia 50%

Europe 15%

Other 4%

North America 31%

HIGHLIGHTS / STATISTICS FROM PRIOR YEAR

400+ DELEGATES

50INNOVATIVE COMPANIES

FROM AROUND THE WORLD PRESENTING THEIR STORY

27COUNTRIES

1,270+BIO ONE-ON-ONE

PARTNERING MEETINGS

250+COMPANIES

REPRESENTED

#BIOASIA20 • bio.org/asia1CE NVESTORCONFERENCE

http://www.bio.org/ceo

2019 Advisory CommitteeEach year, BIO assembles a group of industry thought leaders to help us shape the conference program and provide input on key topics and themes that deliver excellence for all attendees.

HENRY CHEN, JDManaging Partner, Delos Capital

SHINICHIRO KOMOTOPartner, Eight Roads

CHARLES STACEY, MDChief Executive Officer, Cerecin

KYLE HATHAWAY, PHDDirector of Policy and Government Relations, Asia Pacific, MSD, Merck

BO LIU, PHDPrincipal, Venture Investments, Johnson & Johnson Development Corporation – JJDC, Inc. (JJDC)

TED TANAKAPartnering Consultant, Tanaka International LLC

APO HUANG, PHDSecretary General, Taiwan Bio Industry Organization

ARLENE MORRISChief Executive Officer, Willow Advisors

GIL VAN BOKKELEN, PHDChairman and Chief Executive Officer, Athersys

TARO INABAManaging Partner, Remiges Ventures

KYLE MURPHYManaging Director and Founder, KMG Japan

DAMIEN VILLENEUVEVice President, Business Development Asia-Pacific and Japan, Lupin

YUICHI IWAKI, MD, PHDPresident and Chief Executive Officer, MediciNova

TORU SEO, PHDSenior Director, Head, External R&D Innovation Japan, Worldwide Research & Development, Pfizer, Inc.

HAYATO WATANABEVice President, Tokyo, Locust Walk

AMY JACKSONJapan Representative, PhRMA

BT SLINGSBY, MD, PHD, MPHCEO & Executive Director, Global Health Innovative Technology (GHIT) Fund

DALE YAKINManaging Director, VelocityHealth Securities

PATRICK FLOCHELGlobal Life Sciences Sector Leadership Team, Tokyo, Ernst & Young

RYO KUBOTA, MD, PHDRepresentative Executive Officer, Chairman, President and Chief Executive Officer, Kubota Pharmaceutical Holdings Co., Ltd.

RAMI SUZUKI, PHDSenior Director, Head of Japan Business Development, The Janssen Pharmaceutical Companies, Johnson & Johnson

TAKAFUMI YAMAMOTOChief Executive Officer and President, TODAI TLO

Apply to join the

2020 Committee by emailing your interest to

[email protected]



How is the Drug Pricing Reform Initiative Affecting Patient Access, Investment, and Innovation in Japan?The Japanese government is pursuing a series of policy reforms that affect the pricing of medicines involving new cost-effectiveness frameworks and other reimbursement guidelines that poorly align with the value of biotechnology innovations, many of which are already treating patients successfully in other countries.

Reshaping Tumor Microenvironments via ImmunotherapiesThe panelists discussed the next wave of innovation in immunotherapies—how tumor microenvironments develop to create treatments able to demonstrate more durable effects on shrinking tumors across wider ranges of patients.

Turning RNA Interference Research into MedicinesThe approval of the first siRNA-based therapeutic this year has opened the door for companies to pursue expansion of this class of medicines. Deal activity, the progress of academics, and a favorable regulatory environment in Japan have contributed to interest in the field. The discussion included updates on current approaches and techniques for this pipeline of therapeutics.

Bridging External Innovation and Internal R&D for New Patient TherapiesStrategic cross-border application of licensing agreements accelerates the path of an idea for a new medicine to get from the research laboratory to the patient needing treatment.

Education and Conference ProgrammingGeneral themes at the BIO Asia International Conference focus on deal-making trends in the Japanese market, adapting clinical trial strategies across regulatory regimes, and shifts in Asian investment patterns among different therapeutic development specialties.

Explaining CFIUS and New Investment Regulations in the United StatesMarket participants were updated on the evolving national security review process and its impact on the biotechnology industry, as well as how additional rules may impact future business development and investment opportunities.

Biotech Incubator Business Models: Lessons and Needed ImprovementsCorporate biopharmas have decades of experience with university collaborations and open incubator models that produce research and pre-clinical data, but disappointingly few new medicines. What features of incubators create value and where should incubator business model innovation go next? This panel will consider lessons learned from different sized organizations in different geographies and therapeutic areas that have attempted to improve R&D with external collaborators.

Using M&A for Data Advantages Beyond Product PipelinesTakayuki Ooka, Partner, Valuation, Modeling & Economics, Ernst & Young Transaction Advisory Services Co. led a conversation about domestic and international biopharma deal trends, pinpointing regional opportunities to specialize or build value though digitizing R&D workflow.

2019 BIO ASIA CONFERENCE RECAP



REPRESENTATIVE PROGRAM SPEAKERSJun Bao, PhD President and Chief Executive Officer Impact Therapeutics

Michael ChanHead of International Issuer BusinessHong Kong Exchanges and Clearing Limited (HKEX)

Niels Emmerich, PhDVice PresidentGlobal Head Search & Evaluation, AbbVie

Lei Gao, PhDExecutive VP/Deputy GMHarbin Pharmaceutical Group Co., Ltd.

Pingsheng Hu, PhDPresident and Chief Executive OfficerSinorda Biomedicine Ltd.

Hardy TS Kagimoto, MDChairman and CEOHealios K.K.

Lindi Tan, PhDChief Financial OfficerAscletis Pharma Inc.

Masako NakamuraHead of AsiaAlnylam PharmaceuticalsPresident and Representative DirectorAlnylam Japan K.K.

Gil Van Bokkelen, PhDChairman and CEOAthersys

Michael Wang, PhDVice President China BD and Alliance ManagementBrii Biosciences

Hayato WatanabePartnerLocust Walk

Types of Presenting Companies

Privately Funded Company74%

Publicly Traded Company

21%

Philanthropy 2%

Company Presentations The BIO Asia International Conference assembles U.S. and European drug development companies, as well as Asian biotech and pharmaceutical companies interested in research collaborations and licensing agreements. Presenting companies at the event are biopharmas ready to engage in cross-border partnerships and licensing discussions.

Development Phase of Presenting

Companies

Discovery7%Other/Not Applicable

17%

Pre-Clinical26%

Phase I21%

Phase II12%

Phase III12%

Multiple Products in Market

5%



PartneringBIO One-on-One Partnering is the most efficient way to do business in the biotech and pharma industry without traveling all over the world. Our system makes it easy to search for and identify potential partners and request meetings with prospective biotech investors and senior business development executives.

Genitourinary disease 3%

Primary Therapeutic Areas

By Scheduled Meetings

Endocrine disease 4%

Neurological disease

11%

Gastrointestinal disease

7%

Neoplasm11%

Cardiovascular disease

7%Infectious disease

7%

Dermatological disease 6%

Hermatological disease 6%

Respiratory disease 5%

Inflammatory disease 4%

Metabolic disorder 3%

Ocular disease 2%Musculoskeletal disorder 2%

Gynecology and obstetrics 5%

Immune disorder 5%

Seniority Level of Attendees

CEO-level20%

Other25%

Other C-suite10%

VP-level19%

BD DIRECTOR-LEVEL26%

3ZA. Menarini IFRAb Studio AbbVieAbcuroAccelerated Biosciences Corp.Acorda TherapeuticsACT GenomicsAduro AsiaAfricaBioAIMM Therapeutics BVAivita Biomedical Ajinomoto AlivaMab Discovery Services &

AblexisAlnylam PharmaceuticalsAMAG PharmaceuticalsAmerican BriVision (Holding)

CorporationAmgenAMRA MedicalAnaBiosAnima Biotech Aquilo PartnersAscent TherapeuticsAscletis Pharma AsiaBioNext PteASLAN PharmaceuticalsAspect BiosystemsAstraZenecaAthersysAUM BiosciencesAurora Partners K.K.Avilex PharmaBaselArea.swissBayer YakuhinBayer Beigene Switzerland GmbHBeijing Taiyangsheng High-Tech

Pharmaceutical Berlin Partner for Business and

TechnologyBioCentury BioInspiraBioInvent International ABBiomere Techbioskin GmbHBioXcel TherapeuticsBlirtBoehringer Ingelheim JapanBoston PharmaceuticalsBPN Life Science

Brandenburg InvestBridge BiotherapeuticsBrii BiosciencesBusiness France Japan CanBas Can-Fite BioPharmaCaprion BiosciencesCasebia TherapeuticsCellerant TherapeuticsCELLSEED Cerecin ChemRar RDIChitose Biologics Cidara TherapeuticsCiplaCity of SapporoCK Biotech Clarivate AnalyticsCopenhagen CapacityCovance Japan Crux Health TechnologiesCSL Behring K.K.Daewoong PharmaceuticalDaiichi Sankyo Co.Daré BioscienceDeerfield ManagementDelta-Fly PharmaDevelopment Center for

BiotechnologyDonnelley Financial SolutionsDyDo PharmaEditForceEight Roads VenturesEli Lilly and CompanyEmbassy of ItalyEmbassy of the Federal Republic of

GermanyEndoceuticsEphyX NeuroscienceEpiVaxErnst & Young EvecFIMECS Flanders Investment & TradeFuji Yakuhin G M ENTERPRISESGE HealthcareGenesis Healthcare K.K.GenmabGEXVal Global Health Innovative

Technology Fund

Golden Biotechnology Corp.Government of Alberta Japan

OfficeGreen Cross Corporation (GC

Pharma)HanaVax Hangzhou Sinorda PharmaceuticalHarbin PharmaHua MedicineHuons Co.iHeart Japan CorporationI-Mab BiopharmaImmune DesignImpact TherapeuticsIndena SpAIndustrial Technology Research

InstituteInformaInnovation Center/CJ HealthCareInsilico TaiwanInveniAIInvest in BogotaIRBM SpAIsofol Medical AB (publ)Japan Bioindustry AssociationJemincare Therapeutics CorpJiangsu Atom Bioscience and

PharmaceuticalJSR CorporationJT PharmaJuvabis AGKAC Co.Kaken Pharmaceutical Kaunas University of TechnologyKinoPharmaKitov PharmaKleo PharmaceuticalsKMG JapanKolon Life ScienceKyowa Hakko KirinLegoChem BiosciencesLife BiosciencesLife Science Innovation Network

Japan (LINK-J)Locust WalkM Bio Technology Machavert PharmaceuticalsMacroGenicsMcDonnell Boehnen Hulbert &

Berghoff MDNA Life SciencesMedbanks Group

MerckMerck Life Science/BioReliance

End-to-End SolutionsMinervaX Ministry of Science and TechnologyMirati TherapeuticsMSD K.K.Nationl Center for Globale Health

and MedicineNB Health Laboratory Co.NeuroVive PharmaceuticalNewcastle UniversityNEXEL Co.Nitto Boseki Omicsway Oncolys BioPharmaOnconova TherapeuticsOniX Hub & VenturesOptimataPanacea VenturePfizerPfizer Japan/ Corporate Affairs,

Health & Value, New Asset & Access Strategy Group

Pharmaceutical Research and Manufacturers of America

Pierre Fabre MedicamentPoxel SAPrecision Nanosystems Proteina Co.QIMR BerghoferReForm BiologicsRin Institute Rockwell Medical Salzman GroupSamsung BioLogicsSanofi PasteurSansho Santen Pharmaceutical Scohia PharmSecretariat of BioJapan/

Regenerative Medicine JapanSEEDSUPPLY SENAGRO-BUSINESSSensile Medical AGServier ShaperonShenzhen Sanofi Pasteur Biological

ProductsSidleySM Investment GroupSM-Sino Technology Investment

SociumSOUSEIKAI Global Clinical

Research CenterSouthern Star Research Pty SPA Les Laboratoires Frater-RazesSpectrum PharmaceuticalsStandigmStelexis TherapeuticsSuda pharmaceuticals Summit Pharmaceuticals

International Corp.SunRock BiopharmaSuntec Medical (Taiwan)SUSMEDSynthetic BiologicsTAGCyx Biotechnologies Taisho PharmaTaiwan Bio Industry OrganizationTakeda / Gene Therapy Center

Austria (GTCA)Takeda Pharmaceutical CompanyTanaka International Tasly Pharmaceutical GroupTaylor Construction ManagementTeikoku Seiyaku Co.The Hong Kong University of

Science and TechnologyTNOTOA EIYO TODAI TLOTokyo Medical and Dental

UniversityToray IndustriesTriannitwoXARU.S. Chamber of Commerce UCB Japan Co.University of ArizonaVelocityHealthVORONOI W Global Capital LimitedWhanin PharmWillow Advisors Xcovery HoldingsY-BiologicsYD Life ScienceYUMAB GmbHZai Lab

2019 PARTICIPATING COMPANIES



Price (USD)

Number of Registrations

Recognition on Conference

Website, Materials and

Signage

Advertisement in Conference

Program

Acces to BIO One-on-One Partnering*

Partnering Suite and Priority

Scheduling of Meetings

Guaranteed Speaking

Opportunity

Showcase Thought Leadership

Program Sponsor $15,000 3

Company Presentations Sponsor $12,500 2

Access Your Target Audience

Welcome Reception Sponsor $10,000 2

Hospitality Sponsor $ 7,500 1

Executive Roundtable Dinner Contact BIO

Tabletop Exhibit Sponsor $ 5,000 1

Maximize Partnering & Deal Making

BIO One-on-One Partnering System Sponsor $12,500 2

Partnering Suite Package $10,000 2

Boost Brand Visibility

Lanyard Sponsor $ 7,500 1

Conference Program Sponsor $ 7,500 1

WiFi Sponsor $ 7,500 1

Attendee Gift Sponsor $ 5,000 1

High Visiblity Onsite Branding Contact BIO

Conference Program Advertisement $ 1,500

2020 Sponsorship Opportunities

*US/EU headquartered service providers do not receive access to the BIO One-on-One Partnering system through attendee registration. To gain access to the Partnering system, consider sponsoring these opportunities.

• Our Sales & Sponsorship team is always ready to support your cross-Pacific event goals. Please feel free to reach out to the team at +1.202.312.9264 or [email protected].


CONFERENCE VENUE AND HOTELGRAND HYATT TOKYO6-10-3 Roppongi Minato-Ku, Tokyo, Japan, 106-0032Bio has reserved a block of hotel rooms for the 2020 BIO Asia Conference.


Showcase Thought Leadership• PROGRAM SPONSORSubject to Availability ..............................................$15,000 USD

• Three (3) complimentary registrations

• One (1) guaranteed speaking opportunity on program (to be determined based on program development)

• One (1) dedicated partnering suite to be used for BIO One-on-One Partnering™ meetings

• Dedicated BIO staff to provide support and optimize scheduling of BIO One-on-One Partnering meetings

• Access to BIO One-on-One Partnering

• One (1) full-page advertisement in conference program

• Opportunity to display promotional materials on sponsor literature table within the main congregating area of the conference

• Recognition as a sponsoring organization on conference website, materials and signage

• COMPANY PRESENTATIONS SPONSORExclusive .....................................................................$12,500 USD

• Two (2) complimentary registrations

• Sponsor recognition on company presentation signage and materials

• Ability to introduce up to ten (10) companies prior to their presentation





Access Your Target Audience• WELCOME RECEPTION SPONSORThree (3) Available.................................................... $10,000 USD


• Sponsor recognition at Welcome Reception

• Two (2) tickets for non-Conference attendee guests to attend the Welcome Reception





• HOSPITALITY SPONSORExclusive .......................................................................$7,500 USD

• One (1) complimentary registration

• Sponsor recognition at continental breakfast and refreshment breaks





• EXECUTIVE ROUNDTABLE DINNERContact BIO for pricing and availability

• Opportunity to curate a premier gathering of high-level Business Development Professionals. Host an exclusive, invitation-only dinner and connect your brand and target audience in an intimate, upscale setting.

• Full details upon request

• TABLETOP EXHIBIT SPONSORFive (5) Available ........................................................ $5,000 USD


• One (1) dedicated 6’ tabletop exhibit space within the main congregating area of the conference (Includes table and two chairs. Tablecloth and promotional materials to be provided by the sponsor.)




7CE NVESTORCONFERENCE

Back to Benefits Breakdown



Maximize Partnering & Deal Making

Boost Brand Visibility• LANYARD SPONSORExclusive .......................................................................$7,500 USD


• Sponsor recognition on lanyards; lanyards distributed to conference attendees





• CONFERENCE PROGRAM SPONSORExclusive .......................................................................$7,500 USD


• Sponsor recognition on front cover of conference program

• One (1) full-page advertisement on inside front cover of conference program




• WIFI SPONSORExclusive .......................................................................$7,500 USD


• Sponsor recognition on customizable WiFi components

• Sponsor recognition and WiFi login information placed on the back of attendee registration badges





• BIO ONE-ON-ONE PARTNERING SYSTEM Exclusive .....................................................................$12,500 USD


• Sponsor recognition on BIO One-on-One Partnering system and printed partnering schedules

• One (1) dedicated partnering suite to be used for BIO One-on-One Partnering meetings






• PARTNERING SUITE SPONSORMultiple Opportunities ............................................ $10,000 USD


• One (1) dedicated partnering suite to be used for BIO One-on-One Partnering meetings










• ATTENDEE GIFT SPONSORExclusive ...................................................................... $5,000 USD


• Opportunity to provide premium handheld giveaway; distributed to conference attendees




• HIGH VISIBILITY ONSITE BRANDING Contact BIO for pricing and availability

• Opportunity to provide custom creative for high-visibility onsite signage such as hanging banners or clings

• Full details upon request

• CONFERENCE PROGRAM ADVERTISEMENTMultiple Opportunities ...............................................$1,500 USD



• Our Sales & Sponsorship team is always ready to support your cross-Pacific event goals. Please feel free to reach out to the team at +1.202.312.9264 or [email protected].

CO-HOSTS®

CONFERENCE SPONSORS

2019 SponsorsDOUBLE HELIX SPONSOR





asia 2020 tokyo - biogo.bio.org/rs/490-ehz-999/images/bio asia japan 2020... · 2020. 6. 14. ·...

Documents